Abstract
The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30
| Original language | English |
|---|---|
| Pages (from-to) | 381-387 |
| Number of pages | 7 |
| Journal | Cancer Informatics |
| Volume | 6 |
| Publication status | Published - 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Alanine aminotransferase
- Anti-inflammatory drugs
- Chronic hepatitis C
- Hepatocellular carcinoma
- Long prognosis
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy. / Mahmood, Sabina; Togawa, Kazumi; Kawanaka, Miwa; Niiyama, Gouichi; Yamada, Gotaro.
In: Cancer Informatics, Vol. 6, 2008, p. 381-387.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An analysis of risk factors for developing hepatocellular carcinoma in a group of hepatitis C patients with stage 3 fibrosis following interferon therapy
AU - Mahmood, Sabina
AU - Togawa, Kazumi
AU - Kawanaka, Miwa
AU - Niiyama, Gouichi
AU - Yamada, Gotaro
PY - 2008
Y1 - 2008
N2 - The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30
AB - The risk of Hepatocellular carcinoma (HCC) is high in HCV-infected patients who have biochemically and histologically active chronic hepatitis. To observe the long prognosis of Chronic Hepatitis C (CHC) patients with stage 3 fibrosis (F3), 55 CHC patients after initial Interferon (IFN) therapy were followed up for up to 12 years (average 9.8 ± 2.3 years). According to the annual average alanine aminotransferase (ALT) levels, patients were grouped into, low (ALT ≦ 30 IU/l); moderate (ALT >30
KW - Alanine aminotransferase
KW - Anti-inflammatory drugs
KW - Chronic hepatitis C
KW - Hepatocellular carcinoma
KW - Long prognosis
UR - http://www.scopus.com/inward/record.url?scp=49649090335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49649090335&partnerID=8YFLogxK
M3 - Article
C2 - 19259418
AN - SCOPUS:49649090335
VL - 6
SP - 381
EP - 387
JO - Cancer Informatics
JF - Cancer Informatics
SN - 1176-9351
ER -